Generated by AI
Summary of Sep 8's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Summary of Sep 8's posts. Generated by AI.
Investors talking about PHVS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor antagonists designed to address hereditary angioedema and related angioedema conditions through on-demand and preventive treatment options. Its current pipeline includes formulations intended for acute attack management as well as longer-acting prophylactic use, reflecting a portfolio built around differentiated oral approaches in a market still served by injectable and other traditional therapies. Pharvaris operates as a research-driven drug developer with activities spanning clinical development, regulatory engagement, and eventual commercialization of therapies for underserved patient populations. The company is headquartered in Zug, Switzerland.
WebsiteGrafenauweg 8
Zug, 6300
Switzerland
The latest articles about PHVS.
2026-10-26. The following slide deck was published by Pharvaris N.V.